OBIO Stock — Orchestra BioMed Holdings Inc.: Cash, EV, Pipeline

Share price

$6.08

Market cap

$365.4M

Cash

$110.0M

Enterprise value

$270.4M

Balance sheet

Cash	$110.0M
Debt	$15.0M
Net cash	$95.0M
Enterprise value	$270.4M
Basic shares	60.1M shares
Fully diluted shares	60.7M shares
Fully diluted market cap	$369.2M
Cash per share	$1.83

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading OBIO daily closes…

Loading price history…

Pipeline assets

AVIM Therapy (Atrioventricular Interval Modulation)

Phase 3 · Active Modality: bioelectronic (cardiac pacing firmware)

Partnerships Medtronic: exclusive license and collaboration for development and commercialization in pacemaker-indicated patients (right of first negotiation in non-pacemaker patients); Ligand: royalty purchase agreement (17% of product revenues until $17M annual threshold, then 4%/4%, stepping up if enrollment milestones not met by Jan 1, 2027)

Indications

Uncontrolled hypertension in pacemaker-indicated patients (Phase 3)

Catalysts

— End Q3 2026
— Q2 2027

Status note Double-blind randomized BACKBEAT global pivotal trial (up to 500 patients) with FDA IDE approval; delivered via Medtronic dual-chamber pacemaker. FDA Breakthrough Device Designations received.

Virtue SAB (Sirolimus AngioInfusion Balloon)

Phase 3 · Active Modality: drug/device combination (angioinfusion balloon)

Partnerships n/a (Terumo development/commercialization agreement terminated October 24, 2025; Terumo retains right of first refusal)

Indications

Coronary in-stent restenosis (Phase 3)
Coronary small vessel disease (Stage not disclosed)
Below-the-knee peripheral artery disease (Stage not disclosed)

Catalysts

— 2027

Status note FDA IDE-approved Virtue Trial (740 patients) randomizes Virtue SAB vs Boston Scientific's AGENT drug-coated balloon. FDA Breakthrough Device Designations for coronary ISR, coronary small vessel disease, and below-the-knee peripheral artery disease.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06059638	Not disclosed	Recruiting	Sponsor	Orchestra BioMed, Inc	—	Hypertension; Hypertension, Systolic; Hypertension, Essential	—
NCT07045194	Not disclosed	Recruiting	Sponsor	Orchestra BioMed, Inc	—	Coronary Artery Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Orchestra BioMed, Inc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	9,556,063	+1,250,000	0.35%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

OBIO — Orchestra BioMed Holdings Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials

Institutional holders